[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1130500, "exercisedValue": 0, "unexercisedValue": 107640504}, {"maxAge": 1, "name": "Dr. Thomas  Diraimondo Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 630000, "exercisedValue": 0, "unexercisedValue": 28001912}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 727500, "exercisedValue": 0, "unexercisedValue": 7877545}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 34, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1990, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janeen  Doyle", "title": "Chief Corporate & Business Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.56, "open": 24.94, "dayLow": 24.55, "dayHigh": 25.6, "regularMarketPreviousClose": 25.56, "regularMarketOpen": 24.94, "regularMarketDayLow": 24.55, "regularMarketDayHigh": 25.6, "payoutRatio": 0.0, "beta": 2.955, "forwardPE": -15.5625, "volume": 361744, "regularMarketVolume": 361744, "averageVolume": 968207, "averageVolume10days": 600050, "averageDailyVolume10Day": 600050, "bid": 24.74, "ask": 25.03, "bidSize": 1, "askSize": 1, "marketCap": 1473462400, "fiftyTwoWeekLow": 22.48, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 157.82588, "fiftyDayAverage": 26.9298, "twoHundredDayAverage": 40.821774, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 520983008, "profitMargins": 0.0, "floatShares": 37076195, "sharesOutstanding": 59175200, "sharesShort": 10671942, "sharesShortPriorMonth": 9651866, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.18030001, "heldPercentInsiders": 0.066599995, "heldPercentInstitutions": 1.1714801, "shortRatio": 8.41, "shortPercentOfFloat": 0.2609, "impliedSharesOutstanding": 60743700, "bookValue": 17.112, "priceToBook": 1.4551193, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -77742000, "trailingEps": -1.36, "forwardEps": -1.6, "enterpriseToRevenue": 55.804, "enterpriseToEbitda": -4.671, "52WeekChange": -0.37874252, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 24.9, "targetHighPrice": 200.0, "targetLowPrice": 25.0, "targetMeanPrice": 84.12167, "targetMedianPrice": 82.5, "recommendationMean": 1.23077, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 1014145984, "totalCashPerShare": 17.138, "ebitda": -111536000, "totalDebt": 22612000, "quickRatio": 58.264, "currentRatio": 58.47, "totalRevenue": 9336000, "debtToEquity": 2.233, "revenuePerShare": 0.164, "returnOnAssets": -0.08161, "returnOnEquity": -0.0932, "grossProfits": -70037000, "freeCashflow": -27013376, "operatingCashflow": -46001000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -12.16613, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "postMarketChangePercent": -1.28514, "postMarketPrice": 24.58, "postMarketChange": -0.32, "regularMarketChange": -0.66, "regularMarketDayRange": "24.55 - 25.6", "corporateActions": [], "postMarketTime": 1749852046, "regularMarketTime": 1749844801, "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 968207, "fiftyTwoWeekLowChange": 2.42, "fiftyTwoWeekLowChangePercent": 0.10765125, "fiftyTwoWeekRange": "22.48 - 71.71", "fiftyTwoWeekHighChange": -46.809998, "fiftyTwoWeekHighChangePercent": -0.6527681, "fiftyTwoWeekChangePercent": -37.874252, "earningsTimestamp": 1746734460, "earningsTimestampStart": 1754424000, "earningsTimestampEnd": 1754856000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.36, "epsForward": -1.6, "epsCurrentYear": -2.11319, "priceEpsCurrentYear": -11.7831335, "fiftyDayAverageChange": -2.0298004, "fiftyDayAverageChangePercent": -0.07537376, "twoHundredDayAverageChange": -15.921774, "twoHundredDayAverageChangePercent": -0.3900314, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -2.58216, "regularMarketPrice": 24.9, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]